The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and structural updates to the device have improved its performance, according to a study presented at the recent Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

In this video, Dante Pieramici, MD, of California Retina Consultants in Bakersfield, California, discusses patient selection, procedural considerations, and emerging evidence of the disease-modifying benefits with continuous drug delivery.

Following is a transcript of his remarks :

I've been involved in the Port Delivery System development since the beginning. I have patients now who have had the device i

See Full Page